Amgen (AMGN) Liabilities and Shareholders Equity (2009 - 2026)

Amgen's Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $92.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 3.51% year-over-year to $92.5 billion; the TTM figure through Mar 2026 stood at $361.1 billion (down 0.51% YoY), while the FY2025 annual figure was $90.6 billion, down 1.36% from the prior year.
• Liabilities and Shareholders Equity was $92.5 billion for Q1 2026 at Amgen, up from $90.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $97.2 billion in Q4 2023 to a low of $59.2 billion in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $84.2 billion across 5 years, with a median of $90.3 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity soared 52.24% in 2023, then fell 5.47% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $65.1 billion in 2022, then surged by 49.19% to $97.2 billion in 2023, then declined by 5.47% to $91.8 billion in 2024, then fell by 1.36% to $90.6 billion in 2025, then increased by 2.12% to $92.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $92.5 billion (Q1 2026), $90.6 billion (Q4 2025), and $90.1 billion (Q3 2025), per Business Quant data.